Proscia is a software company that is accelerating pathology's digital transformation to change the way we understand diseases like cancer.
Proscia is fighting cancer with intelligent software that changes the way the world practices pathology.
Proscia was founded in 2014 by David West, Coleman Stavish and Nathan Buchbinder. The company is headquartered in Philadelphia, Pennsylvania.
Proscia's Concentriq® platform combines enterprise scalability with a broad portfolio of AI applications to accelerate breakthroughs and unlock clinical insights that advance precision medicine.
Proscia is broadening its own portfolio of computational solutions and introducing a growing number of third-party applications onto Concentriq. It will build on the success of its DermAI® and AI breakthrough in melanoma detection as well as extend digital pathology's first suite of process automation solutions beyond Automated QC.
Proscia's Concentriq software is used by 10 of the top 20 pharmaceutical companies as well as over 5,000 pathologists and scientists. The company lists Penn, Johns Hopkins, and the federal government Joint Pathology Center, which has been collecting disease and injury images since the Civil War, among its clients.
Proscia is backed by Scale Venture Partners, Hitachi Ventures, Highline Capital Management, Triangle Peak Partners, Emerald Development Managers, Flybridge Capital, Alpha Intelligence Capital, ROBO Global, and others. The company raised $37M in Series C round on Jun 14, 2022. This brings Proscia's total funding to $70.6M to date.